Compare BTMD & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTMD | BTCS |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.2M | 52.8M |
| IPO Year | 2021 | 2008 |
| Metric | BTMD | BTCS |
|---|---|---|
| Price | $1.69 | $1.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.83 | ★ $5.00 |
| AVG Volume (30 Days) | 340.6K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.63% |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $192,219,000.00 | $16,491,584.00 |
| Revenue This Year | $2.03 | $21.23 |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 304.85 |
| 52 Week Low | $1.27 | $0.96 |
| 52 Week High | $3.58 | $6.15 |
| Indicator | BTMD | BTCS |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 49.84 |
| Support Level | $1.63 | $1.00 |
| Resistance Level | $2.17 | $1.98 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 89.00 | 31.22 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.